GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:ALGEN - FR0004053510 - Common Stock
2.4 EUR
-0.03 (-1.23%)
We assign a fundamental rating of 4 out of 10 to ALGEN. ALGEN was compared to 83 industry peers in the Biotechnology industry. ALGEN has an average financial health and profitability rating. ALGEN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- ALGEN had positive earnings in the past year.
- In the past year ALGEN has reported a negative cash flow from operations.
- In multiple years ALGEN reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: ALGEN reported negative operating cash flow in multiple years.
1.2 Ratios
- With an excellent Return On Assets value of 3.31%, ALGEN belongs to the best of the industry, outperforming 80.72% of the companies in the same industry.
- ALGEN has a Return On Equity of 7.00%. This is amongst the best in the industry. ALGEN outperforms 80.72% of its industry peers.
- With a decent Return On Invested Capital value of 3.17%, ALGEN is doing good in the industry, outperforming 74.70% of the companies in the same industry.
- ALGEN had an Average Return On Invested Capital over the past 3 years of 5.56%. This is significantly below the industry average of 12.74%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.31% | ||
| ROE | 7% | ||
| ROIC | 3.17% |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
1.3 Margins
- ALGEN's Profit Margin of 6.14% is amongst the best of the industry. ALGEN outperforms 80.72% of its industry peers.
- ALGEN has a Operating Margin of 5.97%. This is in the better half of the industry: ALGEN outperforms 75.90% of its industry peers.
- The Gross Margin of ALGEN (94.91%) is better than 91.57% of its industry peers.
- ALGEN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.97% | ||
| PM (TTM) | 6.14% | ||
| GM | 94.91% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ALGEN is destroying value.
- The number of shares outstanding for ALGEN has been reduced compared to 1 year ago.
- ALGEN has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for ALGEN has been reduced compared to a year ago.
2.2 Solvency
- ALGEN has an Altman-Z score of 1.73. This is a bad value and indicates that ALGEN is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 1.73, ALGEN is in the better half of the industry, outperforming 66.27% of the companies in the same industry.
- A Debt/Equity ratio of 0.71 indicates that ALGEN is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.71, ALGEN is in line with its industry, outperforming 49.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.73 |
ROIC/WACC0.44
WACC7.19%
2.3 Liquidity
- A Current Ratio of 2.41 indicates that ALGEN has no problem at all paying its short term obligations.
- ALGEN has a Current ratio of 2.41. This is comparable to the rest of the industry: ALGEN outperforms 51.81% of its industry peers.
- ALGEN has a Quick Ratio of 2.21. This indicates that ALGEN is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 2.21, ALGEN perfoms like the industry average, outperforming 51.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.41 | ||
| Quick Ratio | 2.21 |
3. Growth
3.1 Past
- The Earnings Per Share has been growing slightly by 5.46% over the past year.
- Looking at the last year, ALGEN shows a decrease in Revenue. The Revenue has decreased by -2.21% in the last year.
- ALGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.46% yearly.
EPS 1Y (TTM)5.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.91%
Revenue 1Y (TTM)-2.21%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%-10.34%
3.2 Future
- Based on estimates for the next years, ALGEN will show a decrease in Earnings Per Share. The EPS will decrease by 0.00% on average per year.
- Based on estimates for the next years, ALGEN will show a quite strong growth in Revenue. The Revenue will grow by 10.37% on average per year.
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 16.00, ALGEN is valued correctly.
- 87.95% of the companies in the same industry are more expensive than ALGEN, based on the Price/Earnings ratio.
- ALGEN is valuated rather cheaply when we compare the Price/Earnings ratio to 27.33, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16 | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, ALGEN is valued cheaply inside the industry as 89.16% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 8.21 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.42%
EPS Next 3Y0%
5. Dividend
5.1 Amount
- ALGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EPA:ALGEN (1/14/2026, 7:00:00 PM)
2.4
-0.03 (-1.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners5.68%
Inst Owner ChangeN/A
Ins Owners7.91%
Ins Owner ChangeN/A
Market Cap22.75M
Revenue(TTM)20.95M
Net Income(TTM)1.29M
Analysts86.67
Price Target6.02 (150.83%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16 | ||
| Fwd PE | N/A | ||
| P/S | 1.09 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.24 | ||
| P/tB | 1.84 | ||
| EV/EBITDA | 8.21 |
EPS(TTM)0.15
EY6.25%
EPS(NY)0
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS2.21
BVpS1.94
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.56
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.31% | ||
| ROE | 7% | ||
| ROCE | 3.94% | ||
| ROIC | 3.17% | ||
| ROICexc | 3.17% | ||
| ROICexgc | 3.91% | ||
| OM | 5.97% | ||
| PM (TTM) | 6.14% | ||
| GM | 94.91% | ||
| FCFM | N/A |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ROICexc(3y)6.94%
ROICexc(5y)N/A
ROICexgc(3y)9.99%
ROICexgc(5y)N/A
ROCE(3y)6.91%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
F-Score3
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.88 | ||
| Cap/Depr | 297.91% | ||
| Cap/Sales | 46.7% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.41 | ||
| Quick Ratio | 2.21 | ||
| Altman-Z | 1.73 |
F-Score3
WACC7.19%
ROIC/WACC0.44
Cap/Depr(3y)64.02%
Cap/Depr(5y)125.45%
Cap/Sales(3y)10.32%
Cap/Sales(5y)17.64%
Profit Quality(3y)100.54%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.91%
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.21%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%-10.34%
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
EBIT growth 1Y-28.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year200%
EBIT Next 3Y68.69%
EBIT Next 5YN/A
FCF growth 1Y-380.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.89%
OCF growth 3YN/A
OCF growth 5YN/A
GENOWAY SA / ALGEN.PA FAQ
Can you provide the ChartMill fundamental rating for GENOWAY SA?
ChartMill assigns a fundamental rating of 4 / 10 to ALGEN.PA.
What is the valuation status of GENOWAY SA (ALGEN.PA) stock?
ChartMill assigns a valuation rating of 2 / 10 to GENOWAY SA (ALGEN.PA). This can be considered as Overvalued.
What is the profitability of ALGEN stock?
GENOWAY SA (ALGEN.PA) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for ALGEN stock?
The Price/Earnings (PE) ratio for GENOWAY SA (ALGEN.PA) is 16 and the Price/Book (PB) ratio is 1.24.
What is the financial health of GENOWAY SA (ALGEN.PA) stock?
The financial health rating of GENOWAY SA (ALGEN.PA) is 4 / 10.